pharmaphorum Podcast
by pharmaphorum
Closing the global evidence gap in oncology, with Flatiron Health
About this podcast
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Episodes
The newest 50 of 366 episodes
- Closing the global evidence gap in oncology, with Flatiron Health · 18 minFollowing ESMO 2026, pharmaphorum spoke with Kate Estep, chief product officer at Flatiron Health, a company answering oncology’s toughest questions by learning from the…
- Patients not just at the table, but creating their own: In conversation with Donna Cryer · 22 minArtificial intelligence is now embedded in every stage of drug development, but the patients whose lives depend on those decisions are almost entirely absent from the design…
- AI, start-ups, and the future of human health: AION Labs’ Mati Gill · 20 minIn a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest. AION Labs is a venture studio built by a coalition of pharma…
- ESMO26: Taiho Oncology on improving the lives of patients with cancer, their families, and their caregivers · 17 minAt ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic…
- ESMO26: Lowering toxicity, extending lives, with Syncromune · 11 minAs the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a…
- Menopause is an urgent global health issue: Bayer’s Cecilia Caetano · 31 min*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* By 2030, 1.2 billion women worldwide will be menopausal or post-menopausal - many at…
- AI governance & cybersecurity: Torridon Cyber’s Robbie Tyrie · 23 minEven the most promising innovation still depends on strong governance, resilient operations, and confidence in sensitive data. In a new pharmaphorum podcast, web editor Nicole…
- AI and pharma launch - Within3's Jason Smith · 16 minIndustry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. In a new pharmaphorum podcast, host Nicole Raleigh speaks…
- Bioconvergence & future human health, with Shai Melcer · 30 minBioconvergence is a multidisciplinary research and development approach that merges technologies from biology, engineering, and computation, providing solutions in medicine…
- AI-enabled pharmacovigilance, with Updesh Dosanjh · 31 minArtificial intelligence is dramatically transforming the landscape for every part of pharma. One area where AI is both essential to implement and important to get right is…
- Getting predictive technologies to patients, with Concr · 19 min · Episode 276Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical trials in a significant shift in how regulators think…
- Europe for life sciences and for patients, with BeOne Medicines · 18 min · Episode 275*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Europe continues to offer major life sciences advantages: deep scientific talent…
- Ethical AI & trust-driven innovation: UCB’s Erik Janssen · 16 min · Episode 274*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* When it comes to digital innovation and AI, consideration of using and implementing…
- Delivering prevention at scale, PA Consulting’s James Davis · 16 min · Episode 273Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at scale…
- Understanding Operation Trialblazer, with Dr Harpreet Singh · 36 min · Episode 272For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lighter…
- Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche · 15 min · Episode 271Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are…
- Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran · 30 min · Episode 270The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the agency has…
- CAMP4 on a new class of ASO in gene under expression · 17 min · Episode 269SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor…
- BonelliErede on M&A in Europe: Andrea Carta Mantiglia · 20 min · Episode 268The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how…
- Purespring on nephrology & gene therapy in kidney disease · 15 min · Episode 267Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphorum…
- Parexel: Flawless execution, policy shifts & patient-centric design · 15 min · Episode 266Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. In a new pharmaphorum podcast, web…
- Citius’ Leonard Mazur talks targeted immune therapy for CTCL · 13 min · Episode 265Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune…
- Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey · 15 min · Episode 264The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing…
- Biosimilars & patient access independent of geographies or socioeconomics, with Rebecca Guntern · 13 min · Episode 2632026 is the year of a major wave of pharmaceutical patent expirations, with numerous blockbuster drugs – spanning diabetes, immunology, cardiovascular, oncology, and other…
- Towards a healthier world: Momentum in UK health system transformation, with Lee-Ann Farrell · 24 min · Episode 262In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson, about what delivery will look like in…
- Trustworthy and novel AI in clinical trial planning, with Kris Kaneta · 18 min · Episode 261In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up…
- The cardio-renal-metabolic space and obesity as a chronic disease, with Ramy Younes · 16 min · Episode 260In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism, at…
- On the power of T-cells, with Cedrik Britten · 18 min · Episode 259In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell…
- Why everyone should care about longevity, with Boyang Wang · 27 min · Episode 258Longevity and healthspan have emerged rapidly as an increasingly serious category of healthcare study and investment. But there are a lot of ideas inside the industry and out…
- A philosophical look at market turn in the Age of AI, with John Holodnak · 21 min · Episode 257Today, the life sciences sector is prioritising recruitment of leaders who can scale efficiently in capital-constrained environments, as well as focusing on hybrid…
- Providing patient access to new therapies, with Dean Erhardt · 18 min · Episode 256Pharma and tech companies are working more closely together than ever. As proven by the news of Merck and NVidia’s new partnership, for example. But while the idea of using AI…
- Pushing through barriers to commercial launch success, with Amanjeet Singh Saluja · 19 min · Episode 255Despite billions spent on new technology and improving data analytics, companies continue to struggle with commercial launch success, with around 35% of launches missing…
- Every drug is a story, with Thomas Goetz · 32 min · Episode 254Here at pharmaphorum we tend to focus on the latest developments in the pharmaceutical space. And to be fair, that’s quite a lot to keep us busy. But the history of pharma is…
- Looking to gene therapy for ocular diseases, with Lance Baldo · 13 min · Episode 253In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a clinical-stage biotechnology company harnessing the…
- Creating what nature has not from AI and computational molecular biophysics with Kashif Sadiq · 14 min · Episode 252In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh spoke with Kashif Sadiq, founder and CEO of DenovAI…
- On collaboration, computational chemistry, and cutting-edge AI – with Olga Nissan · 11 min · Episode 251At BIO-Europe Spring 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Dr Olga Nissan, vice president of business development at Evogene, a computational chemistry…
- Making AI work where it matters, with Rob DiCicco · 19 minIn a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, for a conversation on…
- Treating genetic disease at scale with tRNA, with Michelle Werner · 25 minGenetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic disorders, developing…
- AI in clinical development & ‘white space’, with Andrew Mackinnon · 25 minIn a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Mackinnon, senior vice president and executive general manager at Medable, about…
- Collaboration & personalisation in rare disease R&D, with AOP Health’s Melissa Fellner · 12 min · Episode 246For 30 years, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive…
- Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Alice Valder Curran · 24 minSlowly but surely – and just in time for the State of the Union – the full picture of the Trump Administration’s Most-Favoured Nations drug pricing policy is coming into focus…
- On JPM2026 and healthcare investment today, with Jonah Comstock · 18 min · Episode 245Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to…
- On addressing drug waste and ensuring access, with Jeff Harper · 13 min · Episode 244The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs – straining already overburdened…
- From Buzzword to Strategy: Reverba Global Talks Omnichannel Engagement on the pharmaphorum Podcast · 25 minThe term "omnichannel engagement" has become embedded in today’s healthcare conversations. Yet the biopharmaceutical industry often approaches it superficially – treating it as a…
- On quality data for quality learnings, with Lisa Sims · 16 min · Episode 243Outdated training and behaviours impact patient outcomes and can lead to patient risk. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive…
- JPM2026: Broadening AI drug discovery to include the lab, with Yann Gaston-Mathe · 8 min · Episode 242At the JP Morgan Healthcare conference this year, a lot of the discourse around AI drug discovery focused on making the leap from purely in silico drug discovery operations to…
- On AI and equity in the cancer setting, with Mohit Manrao · 22 min · Episode 241The global impact of digital transformation in the last few decades cannot be understated. And now, of course, artificial intelligence (or AI) is making headlines for its…
- JPM2026: AI diagnostics and translational research, with Andrew Beck · 12 min · Episode 240On-site on the sidelines of JP Morgan Healthcare conference in San Francisco this year, pharmaphorum editor-in-chief Jonah Comstock sat down with Andrew Beck, co-founder and CEO…
- Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf · 24 min · Episode 239An increasing prevalence of immunodeficiency and autoimmune disorders has led to increasing demand for plasma-derived immunoglobulin therapies and a need for scalable and…
- Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland · 15 min · Episode 238A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumour cells and cancer cell DNA. In a new pharmaphorum podcast, web editor Nicole Raleigh…








